Assistant Professor of Medicine, Dana-Farber Cancer Institute
Oncology
Dr. David M. Jackman, MD
|
|
Give Review
David Jackman works in the field of Oncology. He went to medical school at Warren Alpert Medical School of Brown University. David M. Jackman, MD is also published. He has 34 publications published. The lastest publication: "A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.' Dr. David M. Jackman is registered with Medicare.
Publications
- Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung Cancer patients are associated with shorter survival.
- A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung Cancer.
- Lung Cancer screening, version 1.2015: featured updates to the NCCN guidelines.
- Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to th...
- Definitive Primary Therapy in Patients Presenting With Oligometastatic Non-Small Cell Lung Cancer.
- Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA.
- Chemotherapy With Erlotinib or Chemotherapy Alone in Advanced Non-Small Cell Lung Cancer With Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.
- Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Patients Treated with EGFR TKI.
- Volumetric tumor growth in advanced non-small cell lung Cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: Developing criteria to conti...
- RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.
- Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.
- Family history of lung Cancer in never smokers with non-small-cell lung Cancer and its association with tumors harboring EGFR mutations.
- The Introduction of Systematic Genomic Testing for Patients with Non-Small-Cell Lung Cancer.
- The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non-Small Cell Lung Cancer with EGFR Mutations.
- Tumoral cavitation in patients with non-small-cell lung Cancer treated with antiangiogenic therapy using bevacizumab.
- A murine lung Cancer co-clinical trial identifies genetic modifiers of therapeutic response.
- Outcomes After Combined Modality Therapy for EGFR-Mutant and Wild-Type Locally Advanced NSCLC.
- Imaging of lung Cancer in the era of molecular medicine.
- CT tumor volume measurement in advanced non-small-cell lung Cancer: Performance characteristics of an emerging clinical tool.
- Development of central nervous system metastases in patients with advanced non-small cell lung Cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
- New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung Cancer: comparison with original RECIST and impact on assessment ...
- EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell Lung carcinoma than FISH, CISH, and immunohistochemistry.
- Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung Cancer patients: results of an online tu...
- Treatment of peritoneal mesothelioma in pediatric patients.
- Current options for systemic therapy in mesothelioma.
- Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type Cancers.
- Effects of erlotinib in EGFR mutated non-small cell lung Cancers with resistance to gefitinib.
- Erlotinib plus bevacizumab in previously treated patients with Malignant pleural mesothelioma.
- Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung Cancer.
- Response and resistance in a non-small-cell lung Cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose ...
- Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate Cancer.
- Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung Cancer patients treated with gefitinib or ...
- Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment.
Schools
The Warren Alpert Medical School Of Brown University
Beth Israel Deaconess Med Center
Dana Farber Can Center
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bile Duct Cancer
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- BlueConnect HMO
- Blue with Managed Care Behavioral Health HMO
- Preferred Blue PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- CoreSource
- EBS-RMSCO
- Fallon Community Health Plan
- First Health (Coventry Health Care) PPO
- Harvard Pilgrim Health Care PPO
- Choice Care PPO
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Neighborhood Health Plan
- Network Health
- Tufts Health Plans
- Tufts PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
Education
-
Brigham and Women's Hospital -
Beth Israel Deaconess Medical Center -
Warren Alpert Medical School of Brown University
Hospital
-
Brigham and Women's Hospital -
Massachusetts General Hospital -
Dana-Farber Cancer Institute
Drug Facts
| NPI NUMBER | 1386622413 | |
| NPPES Provider LastName | JACKMAN | |
| NPPES Provider FirstName | DAVID | |
| NPPES Provider ZIPCode | 021156013 | |
| NPPES Provider State | MA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 281.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1386622413 |
| Last Name Of The Provider | JACKMAN |
| First Name Of The Provider | DAVID |
| View All |
Similar Doctors
|
|
Dr. Andrew X. Zhu, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Elizabeth A. Guancial, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Meghan J. Campo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jennifer A. Ligibel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher Lee Carpenter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kimmie Ng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael Hassett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stacy W. Gray, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Birrer, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michael Postow, MD |
|
|
Dr. Elizabeth I. Buchbinder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Yi-Bin A. Chen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mark S. Huberman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven E. Come, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Rachel Buchsbaum, MD
This Doctor is OpenDoctor Recommended.
|